Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Decision Resources
The Acute Hospital Market Will See a Decline in Sales Through 2022 Due to Genericization of Expensive Agents, According to a New Report from Decision Resources
BURLINGTON, Mass., Dec. 11, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launch of numerous add-on therapies in the acute coronary syndrome (ACS) 12-month posthospital setting will result in market growth from $1.7 billion in 2012 to nearly $2.4 billion in 2022. A number of agents are in development for the secondary prevention of ACS events but particular excitement has been brewing around novel lipid modifying therapies. The cholesteryl ester transfer protein (CETP) inhibitors and the protein convertase substilisin/kexin type 9 (PCSK9) inhibitors are among the most anticipated therapies expected to launch for ACS and are predicted to collectively capture over a quarter of the 12-month posthospital market in 2022.
While there will be growth in the posthospital setting, the Pharmacor advisory service entitled Acute Coronary Syndrome finds that there will be a decrease in ACS drug sales in the acute hospital market between 2012 and 2022. Despite the launch of two new intravenous agents, The Medicines Company's cangrelor and Regado Biosciences' REG-1, generic erosion of key brands such The Medicine's Company's Angiomax will lead to a contraction in this market between now and 2022.
The report also finds that the dynamics of ADP receptor antagonist use are likely to change over the next 10 years. While clopidogrel (Bristol-Myers Squibb/Sanofi's Plavix/Iscover, generics) currently dominates the acute and posthospital settings as the patient share leader, AstraZeneca's ticagrelor is set to obtain a sizeable portion of the ACS population.
"The 12-month posthospital setting represents the most lucrative segment of the ACS market," said Decision Resources Analyst Joseph Dwyer, Ph.D. "There is a healthy pipeline of novel agents that aim to reduce cardiovascular events through different strategies and diverse mechanisms. While novel antithrombotic therapies will have trouble gaining patient share because of fears of excess bleeding, the emerging anti-dyslipidemic agents, like the CETP inhibitors and the PCSK9 inhibitors, could experience more generous uptake."
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
©2012 PR Newswire. All Rights Reserved.